Panniculitis linked to dermatomyositis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational, descriptive project led by the Dermatology Service at CHU de Strasbourg that enrolls patients aged 1 year and older who have a confirmed diagnosis of dermatomyositis and confirmed panniculitis. Cases with an established alternative cause of panniculitis (for example infectious or metabolic) are excluded. Clinical information, skin and subcutaneous tissue histology, and treatment histories will be collected and compared to published descriptions of other panniculitis types, particularly lupus-associated panniculitis. The goal is to characterize patterns that might help clinicians distinguish panniculitis due to dermatomyositis from other causes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subject aged 1 year and older
* With a confirmed diagnosis of dermatomyositis
* With a confirmed diagnosis of panniculitis

Exclusion Criteria:

* Panniculitis for which another cause has been established, particularly infectious and metabolic panniculitis

Where it's running

• Service de dermatologie - CHU de Strasbourg - France
  Strasbourg, France Recruiting

Study contacts

• Study coordinator: Dan LIPSKER, MD
• Email: dan.lipsker@chru-strasbourg.fr
• Phone: 33 3 88 11 50 48

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Anti-CD19/BCMA universal CAR-T cell therapy for refractory autoimmune diseases

  This will try anti-CD19/BCMA universal CAR-T cell therapy in adults with refractory rheumatoid arthritis, dermatomyositis, systemic lupus, or systemic sclerosis to see if it is safe and can control their disease.

  Recruiting The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07558850

• Emapalumab for MDA5-positive RP-ILD in adults

  This study tests whether emapalumab can help adults with anti-MDA5 positive rapidly progressive interstitial lung disease who have dermatomyositis-related conditions.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT07486869

• Long-term follow-up after KYV-101 (CAR T) treatment

  This follow-up will test how long KYV-101 CAR T cells persist and record any delayed side effects in people who previously received KYV-101 for autoimmune diseases like lupus nephritis, myasthenia gravis, stiff person syndrome, rheumatoid arthritis, or multiple sclerosis.

  Recruiting Kyverna Therapeutics · Denver, Colorado · NCT07403188

• Tocilizumab treatment for anti-MDA5 positive dermatomyositis in adults

  This study will try giving tocilizumab or a placebo to adults with anti-MDA5 positive dermatomyositis to see if it improves symptoms and breathing.

  Recruiting Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07377058

• Patient-rooted insights to shape myositis science

  This global project asks people living with myositis (and their care partners) to share experiences and rank research questions so the community can see which issues matter most.

  Recruiting Myositis International Health & Research Collaborative Alliance Foundation · New Orleans, Louisiana · NCT07374107

• Factors linked to severe dermatomyositis in Caribbean adults

  See if specific clinical, demographic, and ancestral factors are linked to more severe dermatomyositis in adults of Caribbean ancestry living in Guadeloupe.

  Recruiting Centre Hospitalier Universitaire de la Guadeloupe · Pointe-à-Pitre · NCT07265999

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.